Trial Profile
A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Abatacept (Primary) ; Influenza virus vaccine; Pneumococcal vaccine
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms ACQUIRE; MTX-IR Study
- Sponsors Bristol-Myers Squibb
- 15 Apr 2018 Final 5 year safety, efficacy and tolerability immunogenicity results of subcutaneous Abatacept in open label extension period published in The Journal of Rheumatology
- 07 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Oct 2013 Vaccine substudy results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.